This module uses fundamental data of Skye Bioscience, to approximate its Piotroski F score. Skye Bioscience, F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Skye Bioscience, Common. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Skye Bioscience, financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Skye Bioscience, Altman Z Score, Skye Bioscience, Correlation, Skye Bioscience, Valuation, as well as analyze Skye Bioscience, Alpha and Beta and Skye Bioscience, Hype Analysis.
Skye
Piotroski F Score
Market Cap
Enterprise Value
Ptb Ratio
Book Value Per Share
Free Cash Flow Yield
Operating Cash Flow Per Share
Average Payables
Capex To Depreciation
Pb Ratio
Free Cash Flow Per Share
Roic
Net Income Per Share
Payables Turnover
Cash Per Share
Pocfratio
Interest Coverage
Capex To Operating Cash Flow
Pfcf Ratio
Days Payables Outstanding
Income Quality
Roe
Ev To Operating Cash Flow
Pe Ratio
Return On Tangible Assets
Ev To Free Cash Flow
Earnings Yield
Net Debt To E B I T D A
Current Ratio
Tangible Book Value Per Share
Graham Number
Shareholders Equity Per Share
Debt To Equity
Capex Per Share
Graham Net Net
Interest Debt Per Share
Debt To Assets
Enterprise Value Over E B I T D A
Short Term Coverage Ratios
Price Earnings Ratio
Operating Cycle
Price Book Value Ratio
Price Earnings To Growth Ratio
Days Of Payables Outstanding
Price To Operating Cash Flows Ratio
Price To Free Cash Flows Ratio
Ebt Per Ebit
Effective Tax Rate
Company Equity Multiplier
Long Term Debt To Capitalization
Total Debt To Capitalization
Return On Capital Employed
Debt Equity Ratio
Quick Ratio
Dividend Paid And Capex Coverage Ratio
Cash Ratio
Cash Conversion Cycle
Cash Flow Coverage Ratios
Price To Book Ratio
Capital Expenditure Coverage Ratio
Price Cash Flow Ratio
Enterprise Value Multiple
Debt Ratio
Cash Flow To Debt Ratio
Return On Assets
Price Fair Value
Return On Equity
Net Borrowings
Total Cashflows From Investing Activities
Other Cashflows From Financing Activities
Capital Expenditures
Total Cash From Operating Activities
Change To Operating Activities
End Period Cash Flow
Change To Netincome
Change To Liabilities
Investments
Change In Cash
Free Cash Flow
Change In Working Capital
Begin Period Cash Flow
Depreciation
Other Non Cash Items
Net Income
Total Cash From Financing Activities
Issuance Of Capital Stock
Stock Based Compensation
Other Current Liab
Total Current Liabilities
Net Tangible Assets
Retained Earnings
Accounts Payable
Other Assets
Other Current Assets
Other Stockholder Equity
Total Current Assets
Common Stock
Property Plant Equipment
Total Assets
Total Stockholder Equity
Other Liab
Cash
Non Current Assets Total
Common Stock Shares Outstanding
Non Current Liabilities Total
Total Liab
Net Invested Capital
Short Long Term Debt
Net Working Capital
Long Term Debt
Capital Stock
Property Plant And Equipment Net
Short Long Term Debt Total
Net Debt
Cash And Short Term Investments
Liabilities And Stockholders Equity
Capital Lease Obligations
Property Plant And Equipment Gross
Short Term Debt
Interest Expense
Net Income Applicable To Common Shares
Income Tax Expense
Tax Provision
Net Interest Income
Selling General Administrative
Operating Income
Net Income From Continuing Ops
Ebit
Research Development
Ebitda
Total Operating Expenses
Reconciled Depreciation
Income Before Tax
Total Other Income Expense Net
Interest Income
Depreciation And Amortization
Gross Profit
Other Operating Expenses
Cost Of Revenue
Probability Of Bankruptcy
At present, Skye Bioscience,'s Net Debt is projected to increase significantly based on the last few years of reporting. The current year's Debt To Assets is expected to grow to 0.42, whereas Short and Long Term Debt Total is forecasted to decline to about 2.8 M. At present, Skye Bioscience,'s Income Quality is projected to slightly decrease based on the last few years of reporting. The current year's ROE is expected to grow to 18.54, whereas Book Value Per Share is forecasted to decline to (0.32).
At this time, it appears that Skye Bioscience,'s Piotroski F Score is Frail. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
The critical factor to consider when applying the Piotroski F Score to Skye Bioscience, is to make sure Skye is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Skye Bioscience,'s auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Skye Bioscience,'s financial numbers are properly reported.
One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Skye Bioscience,'s different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Skye Bioscience, in a much-optimized way.
F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.
Book Value Per Share
(0.32)
At present, Skye Bioscience,'s Book Value Per Share is projected to increase slightly based on the last few years of reporting.
Skye Bioscience, ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Skye Bioscience,'s sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Skye Bioscience,'s managers, analysts, and investors.
Environmental
Governance
Social
About Skye Bioscience, Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Skye Bioscience, Common's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Skye Bioscience, using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Skye Bioscience, Common based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Skye Bioscience, Common is a strong investment it is important to analyze Skye Bioscience,'s competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Skye Bioscience,'s future performance. For an informed investment choice regarding Skye Stock, refer to the following important reports:
You can also try the Commodity Channel module to use Commodity Channel Index to analyze current equity momentum.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Skye Bioscience,. If investors know Skye will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Skye Bioscience, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(3.60)
Return On Assets
(0.30)
Return On Equity
(0.55)
The market value of Skye Bioscience, Common is measured differently than its book value, which is the value of Skye that is recorded on the company's balance sheet. Investors also form their own opinion of Skye Bioscience,'s value that differs from its market value or its book value, called intrinsic value, which is Skye Bioscience,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Skye Bioscience,'s market value can be influenced by many factors that don't directly affect Skye Bioscience,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Skye Bioscience,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Skye Bioscience, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Skye Bioscience,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.